ArticleNCHS data brief2024
Obesity and Severe Obesity Prevalence in Adults: United States, August 2021-August 2023.
Article in NCHS data brief, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 305 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized-Controlled Trial of Semaglutide for Patients With Chronic Low Back Pain and Obesity
Feasibility, Implementation, and Efficacy of a Plant-based Online Weight Loss Through Education and Resources Program and Study (POWER Study)
Who cites it
305 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach.Obesity (Silver Spring, Md.) · 2026Guideline
- Effects of energy-matched low- versus high-carbohydrate diets on glycaemic control, lipid profile, and body composition in healthy adults: a systematic review and meta-analysis of randomised controlled trials.European journal of nutrition · 2026Pooled it
- Outcomes of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1A) and Patients Undergoing Total Hip Arthroplasty (THA): A Systematic Review and Meta-Analysis.The Iowa orthopaedic journal · 2026Pooled it
- Impact of preoperative weight-loss interventions on outcomes after elective non-bariatric surgery: meta-analysis.BJS open · 2025Pooled it
- Time-Restricted Eating Is Feasible and Acceptable and Improves Glycemic Control in Veterans with Spinal Cord Injury and Obesity: A Pilot Trial.Nutrients · 2026Trial
- Trial
- Effects of a Plant-Based Multi-StrainNutrients · 2026Trial
- Wearable-Measured Physical Activity Goal Adherence and Body Composition Change in a 12-Month mHealth Weight Loss Trial.Sensors (Basel, Switzerland) · 2026Trial
- Effects of a 2-Year Primary Care Weight Loss Intervention on Quality of Life in Patients With Obesity.Obesity (Silver Spring, Md.) · 2026Trial
- Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.Obesity (Silver Spring, Md.) · 2026Trial
- Late-life disability following the action for health in diabetes (Look AHEAD) trial.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Trial
- People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment.Obesity (Silver Spring, Md.) · 2026Trial
- Trajectories of Adherence to Study-Prescribed Physical Activity Goals in a mHealth Weight Loss Intervention.Sensors (Basel, Switzerland) · 2025Trial
- Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial.Diabetes, obesity & metabolism · 2025 · on this mapTrial
- Sex differences in the gut microbiome and related metabolites: role in cardiometabolic disease.Gut microbes · 2026Review
- Agreement between people with obesity and their treating physicians on behavioral and psychological phenotypes in real-world obesity care.Obesity pillars · 2026Article
- Obesity and Cardiovascular Disease: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2026.Obesity pillars · 2026Review
- Risk Adjustment in the Medicare Advantage Population Using Encounter Data.Health services research · 2026Article
- Associations between maternal adiposity during pregnancy and neonatal brain cortical development.NeuroImage · 2026Article
- Geographic variation in eligibility and uptake of GLP-1 receptor agonists for obesity in US adults.American journal of preventive cardiology · 2026Article
245 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This report provides prevalence estimates of adult obesity and severe obesity during August 2021-August 2023 by age and sex, as well as obesity prevalence by education level. Trends in the prevalence of adult obesity and severe obesity over the previous 10 years are also shown. Methods: Data from the August 2021-August 2023 National Health and Nutrition Examination Survey (NHANES) were used for prevalence estimates, incorporating examination survey sample weights into the analysis and accounting for the survey's complex, multistage probability design. Measured height and weight were used to calculate body mass index (BMI) to define obesity (BMI at or above 30) and severe obesity (BMI at or above 40). Differences between estimates overall, among subgroups, and compared with 2017-March 2020 were evaluated using Key findings: During August 2021-August 2023, the prevalence of obesity in adults was 40.3%, with no significant differences between men and women. Obesity prevalence was higher in adults ages 40-59 than in ages 20-39 and 60 and older. The prevalence of obesity was lower in adults with a bachelor's degree or more than in adults with less education. The prevalence of severe obesity in adults was 9.4% and was higher in women than men for each age group. From 2013-2014 through August 2021-August 2023, the age-adjusted prevalence of obesity did not change significantly, while severe obesity prevalence increased from 7.7% to 9.7%.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.